Background: Canine parvovirus (CPV-2) enteritis is a major cause of mortality in young dogs worldwide. Traditional supportive therapy achieves 80–90% survival but does not directly target the virus. Objective: This review systematically analyzes recent advances in CPV-2 therapy, including monoclonal antibodies (Trutect™), recombinant interferon-ω, and fecal microbiota transplantation (FMT). Methods: A structured literature search was performed in PubMed, Web of Science, Scopus, and Google Scholar (2015–2026) using keywords: "canine parvovirus", "CPV-2", "monoclonal antibodies", "interferon-ω", "FMT". Inclusion criteria: original research, clinical trials, guidelines. Exclusion criteria: conference abstracts, preprints, non-peer-reviewed sources. Results: Monoclonal antibody therapy (Trutect™) increases survival to 93% and reduces hospitalization by 1.87 days. Recombinant interferon-ω reduces enteritis severity. FMT accelerates clinical resolution. CPV-2c variant shows reduced vaccine sensitivity (4–8 fold). A practical treatment algorithm is proposed. Conclusions: Targeted therapies significantly improve outcomes. Future research requires randomized controlled trials, global variant surveillance, and next-generation vaccines.
Pavel Shulga (Mon,) studied this question.